News & Updates
Search Research Content
Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.
|Title||Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF.|
|Publication Type||Journal Article|
|Year of Publication||2011|
|Authors||Smith DB, Jones RJ, Cho E, Kowalski J, Karp JE, Gore SD, Vala M, Meade B, Baker SD, Zhao M, Piantadosi S, Zhang Z, Blumenthal G, Warlick ED, Brodsky RA, Murgo A, Rudek MA, Matsui WH|
|Date Published||2011 Jan|
Pharmacologic differentiating agents have had relatively limited clinical success outside of the use of ATRA in acute promyelocytic leukemia and DNA methyltransferase inhibitors in myelodysplastic syndromes. The differentiating effects of such agents can be enhanced in combination with lineage-specific growth factors. We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF.
|Alternate Journal||Leuk. Res.|